Acelity V.A.C. Ulta Original instructions

EN
V.A.C.ULTA™ NEGATIVE
PRESSURE WOUND THERAPY
SYSTEM
(V.A.C.ULTA™ THERAPY SYSTEM)
SAFETY INFORMATION AND V.A.C.
VERAFLO CLEANSE CHOICE™ DRESSING
SYSTEM APPLICATION INSTRUCTIONS
Rx Only
ONLY FOR USE WITH THE KCI V.A.C.ULTA™ THERAPY SYSTEM

TABLE OF CONTENTS
Indications for Use ..................................................................................................................... 4
Transitioning V.A.C.®Therapy Into Home Care ........................................................................... 5
V.A.C.Ulta™ Therapy System Contraindications ......................................................................... 5
Additional Contraindications Specific to V.A.C. VeraFlo™ Therapy.............................................. 5
V.A.C.Ulta™ Therapy System Warnings...................................................................................... 6
Additional Warnings for V.A.C. VeraFlo™ Therapy ..................................................................... 10
V.A.C.Ulta™ Therapy System Precautions................................................................................... 10
Additional Precautions for V.A.C. VeraFlo™ Therapy .................................................................. 12
Additional Precautions for V.A.C. GranuFoam Silver™ Dressing.................................................. 13
V.A.C. VeraFlo Cleanse Choice™ Dressing System Application Instructions................................. 14
Dressing Description .................................................................................................................. 14
V.A.C. VeraFlo Cleanse Choice™ Dressing System Component Identification.............................. 15
Accessories needed for V.A.C. VeraFlo™ Therapy with the
V.A.C.Ulta™ Therapy System (provided separately)..................................................................... 15
Dressing Changes ...................................................................................................................... 16
Wound Preparation.................................................................................................................... 16
V.A.C. VeraFlo Cleanse Choice™ Dressing Application ............................................................... 18
V.A.C.®Advanced Drape Application.......................................................................................... 20
V.A.C. VeraT.R.A.C.™ Pad Application ....................................................................................... 21
V.A.C. VeraT.R.A.C. Duo™ Tube Set Application......................................................................... 22
Instill Pad Application................................................................................................................. 22
SensaT.R.A.C.™ Pad Application ................................................................................................ 23
Initiate V.A.C. VeraFlo™ Therapy................................................................................................ 24
Bridge Application ..................................................................................................................... 26
Using V.A.C. VeraFlo Cleanse™ Dressing.................................................................................... 26
Using V.A.C. VeraFlo Cleanse Choice™ Dressing in Conjunction
with Bandages, Garments or Off-Loading Devices...................................................................... 28

4
The V.A.C.Ulta™ Negative Pressure Wound Therapy System (V.A.C.Ulta™ Therapy System) is an
integrated wound therapy system that can deliver either:
• V.A.C. VeraFlo™ Therapy (Instillation), which consists of negative pressure
wound therapy (V.A.C.®Therapy) coupled with controlled delivery and
drainage of topical wound irrigation treatment solutions and suspensions over
the wound bed.
OR
• V.A.C.®Therapy, which consists of negative pressure wound therapy alone.
When using V.A.C. VeraFlo™ Therapy (Instillation), there are important
Contraindications, Warnings, and Precautions that should be considered
in addition to the Contraindications, Warnings and Precautions for V.A.C.®
Therapy. Contraindications, Warnings and Precautions specific to V.A.C.
VeraFlo™ Therapy are highlighted in grey throughout the document and are
identified by the V.A.C. VeraFlo™ Therapy symbol to the left of the text. When
using V.A.C.®Therapy alone, the V.A.C. VeraFlo™ Therapy Contraindications,
Warnings and Precautions are not applicable.
The V.A.C.Ulta™ Therapy Unit is for use only with V.A.C.®Dressings (V.A.C.®
GranuFoam™, V.A.C. GranuFoam Silver™, V.A.C.®WhiteFoam, V.A.C. VeraFlo™, V.A.C.
VeraFlo Cleanse™ and V.A.C. VeraFlo Cleanse Choice™ Dressing Systems) and
disposables. V.A.C. VeraFlo™ Therapy should only be delivered with V.A.C. VeraFlo™
Dressings and disposables.
NOTE: The V.A.C. GranuFoam Silver™ Dressing is not intended to be used
with V.A.C. VeraFlo™ Therapy because instillation solutions may negatively
impact the benefits of the V.A.C. GranuFoam Silver™ Dressing.
IMPORTANT: As with any prescription medical device, failure to consult a physician and carefully
read and follow all therapy unit and dressing instructions and safety information prior to each use
may lead to improper product performance and the potential for serious or fatal injury. Do not
adjust therapy unit settings or perform therapy application without directions from / or supervision
by the clinical caregiver.
INDICATIONS FOR USE
The V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management
system that provides Negative Pressure Wound Therapy with an instillation option.
Negative Pressure Wound Therapy in the absense of instillation is intended to create an
environment that promotes wound healing by secondary or tertiary (delayed primary) intention by
preparing the wound bed for closure, reducing edema, promoting granulation tissue formation
and perfusion, and by removing exudate and infectious material. The instillation option is
indicated for patients who would benefit from vacuum assisted drainage and controlled delivery
of topical wound treatment solutions and suspensions over the wound bed.
The V.A.C.Ulta™ Negative Pressure Wound Therapy System with and without instillation is
indicated for patients with chronic, acute, traumatic, sub-acute and dehisced wounds, partial-
thickness burns, ulcers (such as diabetic, pressure and venous insufficiency), flaps and grafts.

5
TRANSITIONING V.A.C.®THERAPY INTO HOME CARE
The V.A.C.Ulta™ Therapy System is not intended for home use.
If there is a need to continue V.A.C.®Therapy when a patient
transitions home, consider using other KCI Therapy Systems
approved for the post-acute care environment. Refer to the
safety information included with those devices for important
information.
V.A.C.ULTA™ THERAPY SYSTEM CONTRAINDICATIONS
• Do not place foam dressings of the V.A.C.Ulta™ Therapy System (including both V.A.C.®
Therapy and V.A.C. VeraFlo™ Therapy Dressings) directly in contact with exposed blood
vessels, anastomotic sites, organs or nerves.
NOTE: Refer to Warnings section for additional information concerning Bleeding.
• V.A.C.®Therapy and V.A.C. VeraFlo™ Therapy are contraindicated for patients with:
• Malignancy in the wound
• Untreated osteomyelitis
NOTE: Refer to Warnings section for Osteomyelitis information.
• Non-enteric and unexplored fistulas
• Necrotic tissue with eschar present
NOTE: After debridement of necrotic tissue and complete removal of eschar, V.A.C.®
Therapy may be used.
• Sensitivity to silver (V.A.C. GranuFoam Silver™ Dressing only)
ADDITIONAL CONTRAINDICATIONS SPECIFIC TO V.A.C. VERAFLO™
THERAPY
• Do not use V.A.C.®Dressings with Octenisept®*, hydrogen peroxide or
solutions that are alcohol-based or contain alcohol.
• Do not deliver fluids to the thoracic or abdominal cavity due to the potential
risk to alter core body temperature and the potential for fluid retention within
the cavity.
• Do not use V.A.C. VeraFlo™ Therapy unless the wound has been throughly
explored due to the potential for inadvertent instillation of topical wound
solutions to adjacent body cavities.
*Not available in the United States. Brand name referenced is not a trademark of
KCI, its affiliates, or licensors.

6
V.A.C.ULTA™ THERAPY SYSTEM WARNINGS
Bleeding: With or without using V.A.C.®Therapy or V.A.C. VeraFlo™ Therapy, certain
patients are at high risk of bleeding complications. The following types of patients are at
increased risk of bleeding, which, if uncontrolled, could be potentially fatal.
• Patients who have weakened or friable blood vessels or organs in or around the wound
as a result of, but not limited to:
• Suturing of the blood vessel (native anastamoses or grafts) / organ
• Infection
• Trauma
• Radiation
• Patients without adequate wound hemostasis
• Patients who have been administered anticoagulants or platelet aggregation inhibitors
• Patients who do not have adequate tissue coverage over vascular structures.
If V.A.C.®Therapy or V.A.C. VeraFlo™ Therapy is prescribed for patients who have
an increased risk of bleeding complications, they should be treated and monitored
in a care setting deemed appropriate by the treating physician.
If active bleeding develops suddenly or in large amounts during V.A.C.®Therapy or
V.A.C. VeraFlo™ Therapy, or if frank (bright red) blood is seen in the tubing or in the
canister, immediately stop therapy, leave dressing in place, take measures to stop
the bleeding, and seek immediate medical assistance. The V.A.C.Ulta™ Therapy
Unit and dressings (both V.A.C.®Therapy and V.A.C. VeraFlo™ Therapy) should not
be used to prevent, minimize or stop vascular bleeding.
• Protect Vessels and Organs: All exposed or superficial vessels and organs in or around
the wound must be completely covered and protected prior to the administration of
V.A.C.®Therapy or V.A.C. VeraFlo™ Therapy.
Always ensure that V.A.C.®Foam Dressings and V.A.C. VeraFlo™ Foam Dressings do
not come in direct contact with vessels or organs. Use of a thick layer of natural tissue
should provide the most effective protection. If a thick layer of natural tissue is not
available or is not surgically possible, multiple layers of fine-meshed, non-adherent
material may be considered as an alternative, if deemed by the treating physician to
provide a complete protective barrier. If using non-adherent materials, ensure that they
are secured in a manner as to maintain their protective position throughout therapy.
Consideration should also be given to the negative pressure setting and therapy mode
used when initiating therapy.
Caution should be taken when treating large wounds that may contain hidden vessels,
which may not be readily apparent. The patient should be closely monitored for bleeding
in a care setting deemed appropriate by the treating physician.

7
• Infected Blood Vessels: Infection may erode blood vessels and weaken the vascular wall
which may increase susceptibility to vessel damage through abrasion or manipulation.
Infected blood vessels are at risk of complications, including bleeding, which,
if uncontrolled, could be potentially fatal. Extreme caution should be used
when V.A.C.®Therapy or V.A.C. VeraFlo™ Therapy is applied in close proximity
to infected or potentially infected blood vessels. (Refer to Protect Vessels and
Organs section.)
• Hemostasis, Anticoagulants and Platelet Aggregation Inhibitors: Patients without
adequate wound hemostasis have an increased risk of bleeding, which, if uncontrolled,
could be potentially fatal. These patients should be treated and monitored in a care
setting deemed appropriate by the treating physician.
Caution should be used in treating patients on doses of anticoagulants or platelet
aggregation inhibitors thought to increase their risk for bleeding (relative to the type
and complexity of the wound). Consideration should be given to the negative pressure
setting and therapy mode used when initiating therapy.
• Hemostatic Agents Applied at the Wound Site: Non-sutured hemostatic agents (for
example, bone wax, absorbable gelatin sponge or spray wound sealant) may, if disrupted,
increase the risk of bleeding, which, if uncontrolled, could be potentially fatal. Protect
against dislodging such agents. Consideration should be given to the negative pressure
setting and therapy mode used when initiating therapy. (Refer to Additional Warnings
for V.A.C. VeraFlo™ Therapy section).
• Sharp Edges: Bone fragments or sharp edges could puncture protective barriers, vessels
or organs causing injury. Any injury could cause bleeding, which, if uncontrolled, could
be potentially fatal. Beware of possible shifting in the relative position of tissues, vessels
or organs within the wound that might increase the possibility of contact with sharp
edges. Sharp edges or bone fragments must be eliminated from the wound area or
covered to prevent them from puncturing blood vessels or organs before the application
of V.A.C.®Therapy or V.A.C. VeraFlo™ Therapy. Where possible, completely smooth and
cover any residual edges to decrease the risk of serious or fatal injury, should shifting of
structures occur. Use caution when removing dressing components from the wound so
that wound tissue is not damaged by unprotected sharp edges.
1000 mL Canister: DO NOT USE the 1000 mL canister on patients with a high risk of
bleeding or on patients unable to tolerate a large loss of fluid volume, including children
and the elderly. Consider the size and weight of the patient, patient condition, wound type,
monitoring capability and care setting when using this canister. This canister is recommended for
acute care (hospital) use only.

8
Infected Wounds: Infected wounds should be monitored closely and may require more frequent
dressing changes than non-infected wounds, dependent upon factors such as wound conditions,
treatment goals and V.A.C. VeraFlo™ Therapy parameters (for the V.A.C.Ulta™ Therapy System).
Refer to dressing application instructions (found in V.A.C.®Dressing and V.A.C. VeraFlo™ Dressing
cartons) for details regarding dressing change frequency. As with any wound treatment, clinicians
and patients / caregivers should frequently monitor the patient’s wound, periwound tissue
and exudate for signs of infection, worsening infection or other complications. Some signs of
infection are fever, tenderness, redness, swelling, itching, rash, increased warmth in the wound
or periwound area, purulent discharge or strong odor. Infection can be serious, and can lead
to complications such as pain, discomfort, fever, gangrene, toxic shock, septic shock and / or
fatal injury. Some signs or complications of systemic infection are nausea, vomiting, diarrhea,
headache, dizziness, fainting, sore throat with swelling of the mucus membranes, disorientation,
high fever, refractory and / or orthostatic hypotension, or erythroderma (a sunburn-like rash).
If there are any signs of the onset of systemic infection or advancing infection at the
wound site, contact a physician immediately to determine if V.A.C.®Therapy or V.A.C.
VeraFlo™ Therapy should be discontinued. For wound infections relating to blood vessels,
please also refer to the section titled Infected Blood Vessels.
Infected Wounds with V.A.C. GranuFoam Silver™ Dressing: In the event of clinical infection,
V.A.C. GranuFoam Silver™ Dressing is not intended to replace the use of systemic therapy or
other infection treatment regimens. V.A.C. GranuFoam Silver™ Dressing may be used to provide
a barrier to bacterial penetration. Refer to the section titled Additional Precautions for V.A.C.
GranuFoam Silver™ Dressing.
Osteomyelitis: V.A.C.®Therapy and V.A.C. VeraFlo™ Therapy should NOT be initiated on a
wound with untreated osteomyelitis. Consideration should be given to thorough debridement of
all necrotic, non-viable tissue, including infected bone (if necessary), and appropriate antibiotic
therapy.
Protect Tendons, Ligaments and Nerves: Tendons, ligaments and nerves should be protected
to avoid direct contact with V.A.C.®Foam Dressings or V.A.C. VeraFlo™ Therapy Foam Dressings.
These structures may be covered with natural tissue or meshed non-adherent material to help
minimize risk of desiccation or injury.
Foam Placement: Always use V.A.C.®Dressings or V.A.C. VeraFlo™ Therapy Dressings from
sterile packages that have not been opened or damaged. Do not place any foam dressing into
blind / unexplored tunnels. The V.A.C.®WhiteFoam Dressing may be more appropriate for
use with explored tunnels. The V.A.C. VeraFlo Cleanse™ Dressing and V.A.C. VeraFlo Cleanse
Choice™ Dressing Cover Layer without holes may be more appropriate for use with explored
tunnels when using V.A.C. VeraFlo™ Therapy. Do not force foam dressings into any area of the
wound, as this may damage tissue, alter the delivery of negative pressure, or hinder exudate and
foam removal. Always count the total number of pieces of foam used in the wound and the
dressing change date and document that number on the drape, in the patient’s chart and on the
foam quantity label attached to the pad tubing (if provided).

9
Foam Removal: V.A.C.®Foam Dressings and V.A.C. VeraFlo™ Therapy Foam Dressings are
not bioabsorbable. Always count the total number of pieces of foam removed from the
wound and ensure the same number of foam pieces was removed as placed. Foam
left in the wound for greater than the recommended time period may foster ingrowth of tissue
into the foam, create difficulty in removing foam from the wound, or lead to infection or other
adverse events. If significant bleeding develops, immediately discontinue the use of the
V.A.C.Ulta™ Therapy System, take measures to stop the bleeding, and do not remove
the foam dressing until the treating physician or surgeon is consulted. Do not resume
the use of the V.A.C.®Therapy or V.A.C. VeraFlo™ Therapy until adequate hemostasis has
been achieved and the patient is not at risk for continued bleeding.
Keep V.A.C.®Therapy and V.A.C. VeraFlo™ Therapy On: Never leave a V.A.C.®Dressing or
V.A.C. VeraFlo™ Therapy Dressing in place without active V.A.C.®Therapy or V.A.C. VeraFlo™
Therapy for more than two hours. If therapy is off for more than two hours, remove the old
dressing and irrigate the wound. Either apply a new V.A.C.®Dressing or V.A.C. VeraFlo™ Therapy
Dressing from an unopened sterile package and restart therapy; or apply an alternative dressing at
the direction of the treating clinician.
Acrylic Adhesive: The V.A.C.®Drape (supplied with V.A.C.®Dressings) and the V.A.C.®Advanced
Drape (supplied with V.A.C. VeraFlo™ Therapy Dressings) have an acrylic adhesive coating, which
may present a risk of an adverse reaction in patients who are allergic or hypersensitive to acrylic
adhesives. If a patient has a known allergy or hypersensitivity to such adhesives, do not use the
V.A.C.Ulta™ Therapy System. If any signs of allergic reaction or hypersensitivity develop, such as
redness, swelling, rash, urticaria or significant pruritus, discontinue use and consult a physician
immediately. If bronchospasm or more serious signs of allergic reaction appear, seek immediate
medical assistance.
Defibrillation: Remove the V.A.C.®Dressing or V.A.C. VeraFlo™ Therapy Dressing if defibrillation
is required in the area of dressing placement. Failure to remove the dressing may inhibit
transmission of electrical energy and / or patient resuscitation.
Magnetic Resonance Imaging (MRI) – Therapy Unit: The V.A.C.Ulta™ Therapy Unit is MR
Unsafe. Do not take the V.A.C.Ulta™ Therapy Unit into the MR environment.
Magnetic Resonance Imaging (MRI) – V.A.C.®Dressings: V.A.C.®Dressings and V.A.C.
VeraFlo™ Therapy Dressings can typically remain on the patient with minimal risk in an MR
environment, assuming that use of the V.A.C.Ulta™ Therapy System is not interrupted for more
than two hours (refer to Keep V.A.C.®Therapy and V.A.C. VeraFlo™ Therapy On above).
NOTE: If using V.A.C. VeraFlo™ Therapy ensure that irrigation fluid or
treatment solutions are fully removed from the dressing prior to stopping
negative pressure wound therapy.
The V.A.C. GranuFoam Silver™ Dressing has been shown to pose no known hazards in an MR
environment with the following conditions of use:
• Static magnetic field of 3 Tesla or less,
• Spatial gradient field of 720 Gauss / cm or less, and
• Maximum whole-body-averaged specific absorption rate (SAR) of 3 W / kg for 15 minutes of
scanning

10
Non-clinical testing under these same conditions produced a temperature rise of <0.4°C.
MR image quality may be compromised if the area of interest is in the same area or relatively close
to the position of the V.A.C. GranuFoam Silver™ Dressing.
Hyperbaric Oxygen Therapy (HBO): Do not take the V.A.C.Ulta™ Therapy Unit into a
hyperbaric oxygen chamber. The V.A.C.Ulta™ Therapy Unit is not designed for this environment
and should be considered a fire hazard. After disconnecting the V.A.C.Ulta™ Therapy Unit, either
(i) replace the V.A.C.®Dressing or V.A.C. VeraFlo™ Therapy Dressing with another HBO compatible
material during the hyperbaric treatment, or (ii) cover the unclamped end of the V.A.C.®Tubing
with moist cotton gauze and completely cover the V.A.C.®Dressing or V.A.C. VeraFlo™ Therapy
Dressing (including tubing) with a moist towel throughout the treatment in the chamber. For HBO
therapy, the V.A.C.®Tubing or V.A.C. VeraFlo™ Therapy Tubing must not be clamped. Never leave
a V.A.C.®Dressing in place without active V.A.C.®Therapy for more than two hours; please refer
to the Keep V.A.C.®Therapy On section.
NOTE: If using V.A.C. VeraFlo™ Therapy ensure that irrigation fluid or
treatment solutions are fully removed from the dressing prior to stopping
negative pressure wound therapy
ADDITIONAL WARNINGS FOR V.A.C. VERAFLO™ THERAPY
Topical Wound Solutions: Topical wound solutions or suspensions may enter
internal body cavities if the wound is open to such cavities. They should not be
infused into wounds with unexplored tunnels or unexplored undermining as they
may enter into unintended cavities.
Pauses in Negative Pressure: Application of V.A.C. VeraFlo™ Therapy will result
in pauses of negative pressure wound therapy, which is not recommended on
wounds requiring continuous V.A.C.®Therapy. Do not use V.A.C. VeraFlo™ Therapy
over unstable structures, such as unstable chest wall or non-intact fascia, on
patients at increased risk of bleeding, highly exudating wounds, on flaps, grafts or
wounds with acute enteric fistulae.
Bioengineered Tissue: V.A.C. VeraFlo™ Therapy is not intended for use with
cellular or accellular bioengineered tissues.
Hemostasis: Patients with difficult or fragile wound hemostasis are at increased
risk of bleeding associated with V.A.C. VeraFlo™ Therapy due to the potential
for disruption of clots or dilution of clotting factors. Do not use V.A.C. VeraFlo™
Therapy where hemostatic agents have been used in the wound bed.
V.A.C.ULTA™ THERAPY SYSTEM PRECAUTIONS
Standard Precautions: To reduce the risk of transmission of bloodborne pathogens, apply
standard precautions for infection control with all patients, per institutional protocol, regardless
of their diagnosis or presumed infection status. In addition to gloves, use gown and goggles if
exposure to body fluids is likely.

11
Continuous Versus DPC (Dynamic Pressure Control) V.A.C.®Therapy: Continuous V.A.C.®
Therapy is recommended over unstable structures, such as an unstable chest wall or non-intact
fascia, in order to help minimize movement and stabilize the wound bed. Continuous therapy is
also generally recommended for patients at increased risk of bleeding, highly exudating wounds,
fresh flaps and grafts, and wounds with acute enteric fistulae.
NOTE: V.A.C. VeraFlo™ Therapy, due to the controlled delivery of wound
irrigation and treatment solutions, provides intermittent V.A.C.®Therapy and
is not recommended in the above wound types or conditions.
Patient Size and Weight: The size and weight of the patient should be considered when
prescribing V.A.C.®Therapy or V.A.C. VeraFlo™ Therapy. Infants, children, certain small adults and
elderly patients should be closely monitored for fluid loss and dehydration. Also, patients with
highly exudating wounds or large wounds in relation to the patient size and weight should be
closely monitored, as they have a risk of excessive fluid loss and dehydration. When monitoring
fluid output, consider the volume of fluid in both the tubing and canister.
Spinal Cord Injury (SCI): In the event an SCI patient experiences autonomic dysreflexia (sudden
changes in blood pressure or heart rate in response to stimulation of the sympathetic nervous
system), discontinue V.A.C.®Therapy or V.A.C. VeraFlo™ Therapy to help minimize sensory
stimulation and seek immediate medical assistance.
Bradycardia: To minimize the risk of bradycardia, V.A.C.®Therapy and V.A.C. VeraFlo™ Therapy
must not be placed in proximity to the vagus nerve.
Enteric Fistulas: Wounds with enteric fistulas require special precautions to optimize V.A.C.®
Therapy. Refer to V.A.C.®Therapy Clinical Guidelines for more detail. V.A.C.®Therapy is not
recommended if enteric fistula effluent management or containment is the sole goal of therapy.
NOTE: V.A.C. VeraFlo™ Therapy should not be used in the presence of
enteric fistula to prevent wound contamination.
Protect Periwound Skin: Consider use of a skin preparation product to protect periwound
skin. Do not allow foam to overlap onto intact skin. Protect fragile / friable periwound skin
with additional V.A.C.®Advanced Drape, skin protectant, hydrocolloid or other transparent film.
Multiple layers of the V.A.C.®Advanced Drape may decrease the moisture vapor transmission rate,
which may increase the risk of maceration. If any signs of irritation or sensitivity to the drape,
foam or tubing assembly appear, discontinue use and consult treating physician. To avoid trauma
to the periwound skin, do not pull or stretch the drape over the foam dressing during drape
application. Extra caution should be used for patients with neuropathic etiologies or circulatory
compromise.
Circumferential Dressing Application: Avoid use of circumferential dressings except in the
presence of anasarca or excessively weeping extremities, where a circumferential drape technique
may be necessary to establish and maintain a seal. Consider using multiple small pieces of
V.A.C.®Advanced Drape rather than one continuous piece to minimize the risk of decreased
distal circulation. Extreme care should be taken not to stretch or pull the drape when securing
it, but let it attach loosely and stabilize the edges with an elastic wrap, if necessary. When using
circumferential drape applications, it is crucial to systematically and recurrently palpate distal
pulses, and assess distal circulatory status. If circulatory compromise is suspected, discontinue
therapy, remove dressing and contact treating physician.

12
Pressure Points: Periodically assess and monitor the location of tubing connectors, caps, clamps
or other rigid components to ensure they do not create inadvertent pressure points in relation to
patient position.
V.A.C.Ulta™ Therapy Unit Pressure Excursions: In rare instances, tubing blockages with
the V.A.C.Ulta™ Therapy Unit may result in brief vacuum excursions to more than 250 mmHg
negative pressure. Resolve alarm conditions immediately. Refer to the V.A.C.Ulta™ Therapy
System User Manual or contact your KCI representative for additional information.
ADDITIONAL PRECAUTIONS FOR V.A.C. VERAFLO™ THERAPY
Suitable Solutions: V.A.C. VeraFlo™ Therapy is intended for use with V.A.C.
VeraFlo™ Therapy disposables and topical wound treatment solutions and
suspensions. Only use solutions or suspensions that are:
• Indicated for topical wound treatment according to solution manufacturer’s
instructions for use. Some topical agents may not be intended for extended
tissue contact. If in doubt about the appropriateness of using a particular
solution for V.A.C. VeraFlo™ Therapy, contact the solution’s manufacturer
about its suitability for saturated topical wound exposure.
• Compatible with V.A.C.®Dressings and disposable components. Contact your
KCI representative for a list of solutions shown to be compatible with V.A.C.®
Dressings and disposable components.
NOTE: Hypochlorous acid solutions applied frequently at high
concentrations can lead to significant material degradation. Consider
utilizing concentrations and exposure durations as low as clinically relevant.
NOTE: The V.A.C. GranuFoam Silver™ Dressing is not intended to be used
with V.A.C. VeraFlo™ Therapy because instillation solutions may negatively
impact the benefits of the V.A.C. GranuFoam Silver™ Dressing.
Canister Changes: Monitor fluid level in canisters frequently during use of the
V.A.C. VeraFlo™ Therapy. Frequent canister changes may be necessary depending
on volume of fluid instilled and wound exudates. At a minimum the canister should
be changed weekly and disposed of according to institutional protocol.

13
ADDITIONAL PRECAUTIONS FOR V.A.C. GRANUFOAM SILVER™
DRESSING
Topical Solutions or Agents: The V.A.C. GranuFoam Silver™ Dressing is not
intended to be used with V.A.C. VeraFlo™ Therapy because instillation solutions
may negatively impact the benefits of the V.A.C. GranuFoam Silver™ Dressing.
Protective Layer: As with all V.A.C.®Foam Dressings, the V.A.C. GranuFoam Silver™ Dressing
should not be placed in direct contact with exposed blood vessels, anastomotic sites, organs or
nerves (refer to section on Protect Vessels and Organs). Intervening non-adherent layers may be
placed between the V.A.C. GranuFoam Silver™ Dressing and the wound surface; however, these
products may compromise the effectiveness of the V.A.C. GranuFoam Silver™ Dressing in the area
covered by the non-adherent layer.
Electrodes or Conductive Gel: Do not allow V.A.C. GranuFoam Silver™ Dressing to come in
contact with EKG or other electrodes or conductive gels during electronic monitoring or when
taking electronic measurements.
Diagnostic Imaging: The V.A.C. GranuFoam Silver™ Dressing contains metallic silver that may
impair visualization with certain imaging modalities.
Dressing Components: Application of products containing silver may cause temporary tissue
discoloration.
Additional warnings and precautions apply to certain V.A.C.®specialty dressings and V.A.C.®
Therapy Units. Please refer to the specific product instructions for use prior to use.
If there are any questions regarding the proper placement or usage of V.A.C.®Therapy, please
refer to the V.A.C.®Therapy Clinical Guidelines for more detailed instructions or contact your local
KCI representative. For additional and most current information, please see KCI’s website at www.
kci1.com (US) or www.kci-medical.com (OUS).

14
V.A.C. VERAFLO CLEANSE CHOICE™ DRESSING SYSTEM
APPLICATION INSTRUCTIONS
DRESSING DESCRIPTION
The V.A.C. VeraFlo Cleanse Choice™ Dressing System is intended for use with V.A.C. VeraFlo™
Therapy as provided by the V.A.C.Ulta™ Therapy Unit. It is designed to facilitate removal of
wound exudate and infectious materials. The V.A.C VeraFlo Cleanse Choice™ Dressing is
composed of three separate pieces of foam:
• A Wound Contact Layer of V.A.C. VeraFlo Cleanse Choice™ Dressing with Holes (8mm)
• A Thin Cover Layer of V.A.C. VeraFlo Cleanse Choice™ Dressing without Holes (8mm)
• A Thick Cover Layer of V.A.C. VeraFlo Cleanse Choice™ Dressing without Holes (16mm)
The Wound Contact Layer and at least one Cover Layer are required for dressing the wound,
unless tunnels or undermining is present. The choice of Cover Layer(s) is dependent on wound
depth. When tunnels or undermining is present, only the Cover Layer should be used in the tunnel
or undermining. Refer to the Dressing Application section for more information.
V.A.C. VeraFlo Cleanse Choice™ Dressing can be used when transitioning from V.A.C. VeraFlo™
Therapy to V.A.C.®Therapy.

15
V.A.C. VERAFLO CLEANSE CHOICE™ DRESSING SYSTEM COMPONENT
IDENTIFICATION
ACCESSORIES NEEDED FOR V.A.C. VERAFLO™ THERAPY WITH THE
V.A.C.ULTA™ THERAPY SYSTEM (PROVIDED SEPARATELY)
V.A.C. VeraFlo
Cleanse Choice™
Dressing Wound
Contact Layer (8mm)
V.A.C. VeraFlo
Cleanse Choice™
Dressing Thin
Cover Layer (8mm)
V.A.C. VeraFlo
Cleanse Choice™
Dressing Thick
Cover Layer (16mm)
V.A.C.®Advanced Drape
(Quantity: 4)
V.A.C.®Ruler
V.A.C.
VeraT.R.A.C.™
Pad
3M™ Cavilon™ No
Sting Barrier Film
(Quantity: 4)
V.A.C. VeraT.R.A.C. Duo™
Tube Set
(optional, refer to
V.A.C. VeraT.R.A.C. Duo™
Tube Set
Application section)
V.A.C.
VeraLink™
Cassette
OR
1000 mL
Canister
500 mL
Canister

16
All V.A.C.Ulta™ Therapy System dressings and accessories are packaged sterile and are made
without natural rubber latex. With the exception of the V.A.C. VeraLink™ Cassette, all disposable
components are for single use only. The V.A.C. VeraLink™ Cassette is for single patient use only.
Re-use of disposable components may result in wound contamination, infection, and / or
failure of the wound to heal. To help ensure safe and effective use, all components should only
be used with the V.A.C.Ulta™ Therapy Unit.
The decision to use clean versus sterile / aseptic technique is dependent upon wound
pathophysiology, physician / clinician preference and institutional protocol. Use appropriate
institutional protocols to avoid inadvertent contamination of exposed components.
DRESSING CHANGES
Wounds being treated with the V.A.C.Ulta™ Therapy System should be monitored on a regular
basis. In a monitored, non-infected wound, V.A.C.®Dressings and V.A.C. VeraFlo™ Therapy
Dressings should be changed every 48 to 72 hours, but no less than three times per week, with
frequency adjusted by the clinician as appropriate. Infected wounds must be monitored often
and very closely. For these wounds, dressings may need to be changed more frequently with
the dressing change intervals based upon a continuing evaluation of wound condition and the
patient’s clinical presentation, rather than a fixed schedule.
Refer to the V.A.C.®Therapy Clinical Guidelines which are available at www.kci1.com or contact
your local KCI representative for a printed copy.
WOUND PREPARATION
WARNING: Review all V.A.C.Ulta™ Therapy System Safety
Information included with the V.A.C.Ulta™ Therapy Unit before
beginning Wound Preparation.
NOTE: If a V.A.C. VeraT.R.A.C.™ Pad or V.A.C. VeraT.R.A.C Duo™ Tube Set is currently in place
on the dressing, consider using the Dressing Soak tool of the V.A.C.Ulta™ Therapy Unit to hydrate
the dressing with sterile water, normal saline or an approved topical solution. This hydration is
intended to facilitate removal of the dressing while potentially reducing patient discomfort during
dressing change. Refer to the V.A.C.Ulta™ Therapy System User Manual for instructions on using
the Dressing Soak tool.
1. Remove and discard previous dressing per institution protocol. Thoroughly inspect wound
to ensure all pieces of dressing components have been removed.
NOTE: If the dressing being removed is a V.A.C.®Dressing or a V.A.C. VeraFlo™ Therapy
Dressing, ensure removal of all pieces of foam. The Log tool on the V.A.C.Ulta™ Therapy
Unit can be used to review the number of foam pieces used in the wound if previously
entered. Refer to the V.A.C.Ulta™ Therapy System User Manual for instructions on using the
Log tool. Refer to Warnings regarding Foam Removal in the Safety Information section.
2. Ensure debridement of all necrotic, non-viable tissue, including bone, eschar, or hardened
slough, as prescribed by treating physician.
3. Perform thorough wound and periwound area cleaning per physician order or institution
protocol prior to each dressing application.

17
4. Protect fragile / friable periwound skin with additional V.A.C.®Advanced Drape, 3M™
Tegaderm™ Dressing, or other similar medical grade transparent film, skin protectant or
hydrocolloid.
NOTE: Depending on region, 3M™ Cavilon™ No Sting Barrier Film may be provided in the
dressing package.
5. Application of the 3M™ Cavilon™ No Sting Barrier Film (if used):
a. Skin should be clean and dry prior to application of 3M™ Cavilon™ No Sting Barrier
Film.
b. Use supplied wipe to apply a uniform coating of film over entire area of concern
(Fig. 1).
c. If an area is missed, reapply to that area only after first application of 3M™ Cavilon™
No Sting Barrier Film has dried (approximately 30 seconds).
d. If 3M™ Cavilon™ No Sting Barrier Film is applied to area with skin folds or other skin-
to-skin contact, make sure that skin-contact areas are separated to allow the film to
thoroughly dry before returning to normal position.
• Allow 3M™ Cavilon™ No Sting Barrier Film to thoroughly dry before covering
with dressings.
• Reapplication of 3M™ Cavilon™ No Sting Barrier Film is necessary each time
dressings are changed; the barrier film is removed by the V.A.C.®Advanced
Drape adhesive.
e. If desired, the film can be removed by using most medical adhesive removers as
directed. Clean and dry the involved area and reapply 3M™ Cavilon™ No Sting Barrier
Film.
6. Ensure adequate hemostasis has been achieved (refer to Warnings, Bleeding section,
Hemostasis, Anticoagulants and Platelet Aggregation Inhibitors).
7. Protect sensitive structures, vessels and organs (refer to Warnings, Bleeding section, Protect
Vessels and Organs).
8. Sharp edges or bone fragments must be eliminated from wound area or covered (refer to
Warnings, Bleeding section, Sharp Edges).
Fig. 1

18
V.A.C. VERAFLO CLEANSE CHOICE™ DRESSING APPLICATION
Refer to V.A.C.®Therapy Clinical Guidelines for detailed instructions for treating different wound
types and for multiple wound applications.
1. Assess wound dimensions and pathology, including the presence of undermining or tunnels
(Fig 2). The V.A.C. VeraFlo Cleanse Choice™ Contact Layer (with holes) is not recommended
for use with tunnels or undermining. Do not place any foam dressing into blind / unexplored
tunnels.
NOTE: A non-adherent material can be used prior to foam dressing placement in order to
facilitate future dressing removal. If adjunct materials are utilized under the V.A.C. VeraFlo
Cleanse Choice™ Dressing, they must be compatible with solution to be instilled and
meshed, porous or fenestrated to allow for effective fluid and exudate removal. Document
on the drape, on the supplied Foam Quantity Label (attached to the V.A.C. VeraT.R.A.C.™
Pad or, if used, the V.A.C. VeraT.R.A.C. Duo™ Tube Set tubing) (Fig. 7) and in the patient’s
chart to ensure removal with subsequent dressing changes.
2. Select the layers (Wound Contact and Cover Layer) of V.A.C. VeraFlo Cleanse Choice™
Dressing to be used in the wound (Fig. 3). The choice of Cover Layer(s) (Thick and / or Thin)
depends on wound depth. Size the dressing layers as needed to allow gentle placement into
the wound without firm packing of the foam, or overlapping onto intact skin (Fig. 4).
CAUTION: Do not cut or tear the foam over the wound, as fragments may fall into the
wound (Fig. 5). Away from wound site, rub foam edges to remove any fragments or loose
particles that may fall into or be left in the wound upon dressing removal.
Fig. 2
Fig. 5
Fig. 3
Fig. 6
Fig. 4
8mm
16mm

19
3. Gently place foam into wound cavity, covering the entire wound base and sides, tunnels and
undermined areas in the following order: (Fig. 6).
• As required, use a Cover Layer to fill explored tunnels and undermined areas.
• Place the Wound Contact Layer with Holes directly into the wound bed.
• Place the selected Cover Layer(s) over the Wound Contact Layer with Holes.
NOTE: Do not use the Wound Contact Layer with Holes in tunnels or undermined areas.
NOTE: Do not force the V.A.C. VeraFlo Cleanse Choice™ Dressing into any areas of the
wound.
NOTE: Do not over-pack the wound cavity. Do not place multiple pieces of foam in
tunnels to prevent foam from being left behind at subsequent dressing changes.
NOTE: If using multiple pieces of foam, ensure foam-to-foam contact between adjacent
pieces of foam for even distribution of fluid and negative pressure.
NOTE: Always note the total number of pieces of foam used in the wound and document
on the drape, on the supplied Foam Quantity Label (attached to the V.A.C. VeraT.R.A.C.™
Pad or, if used, the V.A.C. VeraT.R.A.C. Duo™ Tube Set tubing) (Fig. 7) and in the patient’s
chart.
The Log tool on the V.A.C.Ulta™ Therapy Unit can be used to record the number of foam
pieces used in the wound. Refer to the V.A.C.Ulta™ Therapy System User Manual for
instructions on using the Log tool.
NOTE: Retention sutures should be covered with a single layer of non-adherent wide
meshed, porous or fenestrated material placed between the sutures and the V.A.C.®
Advanced Drape.
V.A.C. VeraFlo™ Dressing
0 cm 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
# of
Foam
Pieces
Date Dressing Applied
Peel
Foam Quantity Label
V.A.C.®Ruler with Foam Quantity Label
Number of foam pieces
used in the wound Fig. 7
Fig. 8

20
V.A.C.®ADVANCED DRAPE APPLICATION
CAUTION: Patient’s skin condition should be carefully monitored (refer to Precautions, Protect
Periwound Skin section).
1. Trim the V.A.C.®Advanced Drape to cover the foam and an additional 3-5 cm border of
intact periwound tissue (Fig. 9). The V.A.C.®Advanced Drape may be cut into multiple pieces
for easier handling. Excess V.A.C.®Advanced Drape may be kept to seal difficult areas, if
needed.
2. Carefully remove Layer 1 to expose adhesive (Fig. 10). The V.A.C.®Advanced Drape may be
held by the Ruler / Handling Bars.
3. Place the adhesive face down over foam and apply V.A.C.®Advanced Drape to cover foam
and intact skin, ensuring V.A.C.®Advanced Drape covers at least a 3-5 cm border of intact
periwound tissue.
4. Remove Layer 2 and pat V.A.C.®Advanced Drape to ensure an occlusive seal (Fig. 11).
NOTE: Proper sealing of the wound with the V.A.C.®Advanced Drape is essential for
assuring therapy is delivered to the wound. Use of V.A.C. VeraFlo™ Therapy in wounds
where large volumes of instillation fluid are delivered to the wound or in wounds in
anatomical locations that are difficult to seal require additional precautions to assure that
the dressing is adequately sealed throughout therapy. Consider adjusting patient placement
during instillation cycle, application of an additional layer of drape in tissue folds or areas
more likely to be susceptible to leaks, and supporting the wound area with surface contact or
pillow to prevent bulging of drape if the wound is in a dependent position.
5. Remove the Ruler / Handling Bars.
Fig. 9 Fig. 10
Fig. 11
Layer 1
Layer 2